evipedia.ai
← Back

Ketoglutaric Acid for Hair Regrowth

Evidence Review created on 08/24/2026 using AI4L / Opus 5

Also known as: Alpha-Ketoglutaric Acid, α-Ketoglutaric Acid, Alpha-Ketoglutarate, AKG, 2-Oxoglutaric Acid, 2-Oxoglutarate, Calcium Alpha-Ketoglutarate, Ca-AKG, Ornithine Alpha-Ketoglutarate, Arginine Alpha-Ketoglutarate

Motivation

Ketoglutaric acid is a small molecule the body makes constantly while turning food into energy, and it is also sold as a supplement, usually bound to calcium. Its blood levels fall steadily with age, which is why researchers who study aging began looking at it.

The link to hair arrived indirectly. Laboratory work on the housekeeping process cells use to clear out their own worn-out parts found that several substances able to switch that process on could also coax resting hair follicles back into a growing phase, and ketoglutaric acid was one of them. Animal feeding studies have since reported denser, better-coloured coats, and a university patent covering hair-growth use was filed a decade ago. None of this has yet been tested on human scalps.

This review examines what is known about ketoglutaric acid and hair regrowth: the mechanisms proposed for and against it, what the animal and cell studies do and do not show, where human evidence exists and where it is missing, the safety profile of the forms on sale, and the practical questions of dose, form, timing and monitoring.

Benefits - Risks - Protocol - Conclusion

High-level sources that discuss ketoglutaric acid itself, or the follicle-cycling mechanism it is proposed to act through, in substantial depth.

Content from three priority platforms could not be included. FoundMyFitness returns only a passing mention of the compound inside a broader supplement-screening news item, with no dedicated piece; Chris Kresser’s site returns only a methylation podcast for this term, with no discussion of the compound or of hair; Life Extension surfaces products but no article on ketoglutaric acid. Five qualifying items were found, so the list is not padded.

Grokipedia

  • α-Ketoglutaric acid

    Covers the molecule’s chemistry, its position in the energy cycle, its enzyme-cofactor roles and its supplement forms, giving useful orientation before the hair-specific literature is read.

Examine

  • Alpha-Ketoglutarate

    Summarises benefits, drawbacks and dosing, noting that studied doses run 3.6–6 g with no established daily recommendation. It does not list hair as an application.

ConsumerLab

  • Does AKG Extend Lifespan and Slow Aging?

    Distinguishes plain, calcium-bound and delayed-release forms, names the brands selling them, and states plainly that good clinical evidence for human lifespan or healthspan benefit is lacking.

Systematic Reviews

Systematic reviews and meta-analyses bearing on this review: four in which ketoglutaric acid or its ornithine salt is an explicitly assessed intervention, none addressing a hair outcome, plus one on the calcium carrier that supplies the principal risk.

On the trade-off central to this review, only one side is represented at systematic-review level: no systematic review or meta-analysis exists for the claimed effect (hair regrowth), while the principal risk — the calcium load carried by calcium-bound formulations — is covered by the pooled calcium-supplement trials listed above. The four ketoglutaric acid reviews stand in for the closest adjacent evidence on the benefit side, tissue repair under catabolic stress.

Mechanism of Action

Ketoglutaric acid sits in the tricarboxylic acid cycle (the loop that turns food into energy). Two roles matter for hair.

First, it is the obligatory partner substrate for the 2-oxoglutarate-dependent dioxygenases (a large iron-requiring enzyme family, reviewed here), including TET enzymes (which strip methyl tags from DNA), JmjC histone demethylases (which strip the same tags from DNA-packaging proteins), collagen prolyl and lysyl hydroxylases (which strengthen collagen), and the prolyl hydroxylases that tag HIF-1α (hypoxia-inducible factor 1α, the master low-oxygen switch) for destruction. Adding substrate nudges them all.

Second, in the hair work it acted through autophagy (the cell’s recycling of worn-out parts). Follicles entering anagen (the active growth phase) showed more autophagy, and autophagy blockers cancelled the effect; the same study grouped ketoglutaric acid with rapamycin and metformin, which act on mTOR (mechanistic target of rapamycin, a cellular growth switch) and AMPK (AMP-activated protein kinase, the low-fuel sensor). Rabbit feeding work instead implicates Wnt/β-catenin signalling (a developmental pathway that builds follicles), and rabbit cell work ERK/Nrf2 signalling (the cell’s master antioxidant switch).

These accounts conflict in direction. Autophagy predicts benefit; feeding prolyl hydroxylases predicts faster HIF-1α breakdown, the opposite of one proposed minoxidil action.

Pharmacologically it is an endogenous metabolite, not a selective drug: its only known receptor is OXGR1 (the 2-oxoglutarate receptor) in kidney, it distributes wherever the cycle runs, it is consumed within minutes or converted to glutamate, it bypasses the cytochrome P450 enzymes that clear most drugs, and surplus leaves via renal organic anion transporters.

Historical Context & Evolution

Ketoglutaric acid was identified in 1937 by Hans Krebs and William Johnson as an intermediate of the cycle that later carried Krebs’s name. Its first deliberate therapeutic use was nutritional, not cosmetic: from the 1970s onward, French clinical nutrition groups gave the ornithine salt to burn, surgical and elderly patients, reporting better nitrogen retention, preserved muscle and faster wound closure — findings that a 2026 systematic review still describes as consistent within its fifteen included studies. Later syntheses reached a different verdict on hard endpoints: an umbrella review found no significant effect on assessed clinical outcomes in burns. Both readings survive, because the original trials measured metabolic markers well and clinical endpoints poorly, and the newer pooling weighted the latter.

The pivot to health optimisation came from model organisms. A 2014 study reported that the metabolite extends roundworm lifespan by inhibiting ATP synthase and TOR (the cell’s energy-making turbine and the growth switch described above); fruit-fly work then implicated that switch and the low-fuel sensor; and in 2020 a Buck Institute mouse study reported longer life and compressed frailty, with coat colour among the phenotypes most clearly protected.

The hair application is younger still. The same University of California, Los Angeles group that published the 2019 anagen-induction study had already filed a patent on keto acids for stimulating hair growth in 2016 — a commercial interest worth naming, since that team supplies essentially all of the hair-specific evidence. The patent has since lapsed.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: there is no randomised or controlled human trial of ketoglutaric acid measuring any hair endpoint — hair count, hair density, shaft diameter, or a validated hair-growth scale — so no replicated human clinical endpoint exists.

Medium 🟩 🟩

No benefit reaches Medium: no single human trial and no observational cohort has measured a hair outcome on ketoglutaric acid, and the only human-derived hair data are genetic-instrument analyses of naturally occurring blood levels, which test an inherited endogenous exposure rather than supplementation.

Low 🟩

Speculative 🟨

Induction of the Growth Phase in Resting Follicles

Applied to mouse skin in telogen (the resting phase), it triggered anagen; autophagy blockers abolished the effect. Mouse-only, and the oral arm of that study used a related keto acid rather than ketoglutaric acid.

Higher Hair-Follicle Density

Rex rabbits fed 1.5% α-ketoglutaric acid for 35 days showed greater primary, secondary and total follicle density, alongside raised Wnt-pathway markers in skin. A livestock coat study with no human counterpart.

Protection of Follicle-Instructing Cells from Oxidative Injury

In rabbit dermal papilla cells (the cluster that instructs a follicle to grow), it blunted hydrogen-peroxide damage through ERK/Nrf2 signalling. Cell-culture only, with no follicle, coat or hair endpoint measured.

Preservation of Coat Colour and Condition

Female mice fed 2% calcium α-ketoglutarate from 18 months lost less fur colour, scored better on coat condition, and carried more pigment-producing cells in hair bulbs. Frailty scoring in mice only.

Lower Estimated Epigenetic Age

A retrospective series of 42 users, analysed by the manufacturer and the test provider, reported an average eight-year fall in methylation-based age estimates. Uncontrolled, financially conflicted, and no hair outcome measured.

Benefit-Modifying Factors

  • Androgen receptor gene variation: In pattern hair loss the AR gene (which encodes the docking protein for testosterone and dihydrotestosterone, the hormone that miniaturises follicles) is the dominant driver. A pro-growth metabolic nudge is unlikely to overcome strong androgen signalling.
  • Enzyme-family gene variants: Variants in IDH1 and IDH2 (which encode the enzymes producing ketoglutaric acid) and FTO (a demethylase that consumes it) shift the endogenous supply and could alter how much a supplemented dose adds.
  • Baseline cofactor status: The enzyme family this compound feeds also requires iron and vitamin C. Low ferritin or poor vitamin C status caps the response, and low ferritin independently sustains hair shedding.
  • Sex-based differences: In the mouse lifespan study the coat-colour and survival effects were clearly female-predominant, with male survival non-significant. Whether that maps to human female-pattern hair loss is untested.
  • Pre-existing follicle status: Scarring alopecias (hair loss in which follicles are replaced by scar tissue) destroy the follicle itself, so no cycling signal can restore growth. Thyroid disease and iron deficiency similarly hold follicles in a shedding state.
  • Age-related considerations: Circulating levels fall with age, so headroom is greatest in older users; the epigenetic-age series reported larger changes in chronologically and biologically older participants. Follicle stem-cell reserve also declines with age.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome has been reported in more than one controlled human trial of ketoglutaric acid, and the controlled human safety record consists of routine laboratory panels in short sports-nutrition and aging-research studies with no replicated adverse signal.

Medium 🟥 🟥

No risk reaches Medium: no single controlled human trial and no consistent observational dataset attributes an adverse clinical event to ketoglutaric acid itself; every concern below rests on the calcium carrier, on uncontrolled reporting, or on genetic-instrument inference.

Low 🟥

Added Calcium Load from Calcium-Bound Forms

Calcium α-ketoglutarate is roughly 22% calcium by weight, so the doses used in aging trials add a meaningful daily increment. Pooled randomised trials link calcium supplements to more myocardial infarction. That evidence concerns calcium, not the ketoglutarate portion, and no trial has tested this salt on vascular endpoints.

Magnitude: About 220 mg elemental calcium per gram of calcium α-ketoglutarate; a meta-analysis of calcium supplement trials reported roughly 27–31% more myocardial infarctions on supplemental calcium without vitamin D.

Gastrointestinal Intolerance

It is a dicarboxylic acid, and gram-level doses can provoke nausea, reflux or diarrhoea; delayed-release forms exist partly for this reason. Reporting comes from uncontrolled supplement use and from mixed-nutrient trials in which it was one ingredient among several.

Magnitude: Not quantified in available studies. The Cochrane review covering ornithine α-ketoglutarate rated gastrointestinal side-effect data very uncertain, and no trial of the compound alone has tabulated symptom rates separately from the rest of the formulation.

Palpitations and Light-Headedness with Arginine-Bound Forms ⚠️ Conflicted

The sports-nutrition salt has been linked with palpitations and light-headedness, plausibly through arginine-driven widening of blood vessels rather than the ketoglutarate. A controlled eight-week trial at 12 g daily reported it safe and well tolerated, so the reports are inconsistent and form-specific.

Magnitude: Not quantified in available studies. The controlled trial of arginine α-ketoglutarate tabulated clinical blood markers rather than symptom incidence, so no event rate can be derived from it.

Possible Increase in Alopecia Areata (Patchy Autoimmune Hair Loss) Risk ⚠️ Conflicted

A Mendelian randomization analysis (inherited gene variants as a natural experiment) placed genetically higher blood α-ketoglutarate among factors raising alopecia areata risk, while cell and animal work points the other way. Net reading: too indirect to establish real risk, but the only human-derived hair finding does not favour benefit.

Magnitude: Direction only — genetically higher circulating levels tracked with higher alopecia areata risk in the primary analysis, a result that held across the sensitivity methods used. The literature reports no outcome figure for supplemental intake, because no trial has measured alopecia areata incidence on ketoglutaric acid.

Speculative 🟨

Theoretical Opposition to Minoxidil’s Enzyme Targets

Minoxidil inhibits lysyl hydroxylase and is thought to stabilise HIF-1α; both enzymes require ketoglutaric acid. Supplying more could blunt either action. In-vitro enzymology only — no study has co-administered the two.

Substrate Supply in Mutant-Enzyme Tumours

In IDH1- or IDH2-mutant cancers, a review of those mutations describes the altered enzyme converting ketoglutaric acid into 2-hydroxyglutarate, which drives tumour growth. Extra substrate is theoretically unhelpful. Biochemical inference only.

Risk-Modifying Factors

  • Calcium-sensing receptor variants: Variants in CASR (which encodes the sensor that sets the calcium set-point) shift how tightly serum calcium is regulated, widening the margin of concern for calcium-bound formulations.
  • Somatic tumour enzyme mutations: IDH1 or IDH2 mutations, found in some gliomas (brain tumours), acute myeloid leukaemias and bile-duct cancers, redirect ketoglutaric acid into a growth-promoting metabolite. This is a somatic, not inherited, modifier.
  • Baseline calcium and kidney markers: Serum calcium in the upper reference range, raised parathyroid hormone, high 24-hour urinary calcium, or reduced kidney filtration all narrow tolerance for the calcium carrier.
  • Sex-based differences: Post-menopausal women carry the highest background calcium supplement exposure and were the group in whom the cardiovascular signal from calcium supplements was clearest, so the carrier matters more in this group.
  • Pre-existing health conditions: Calcium-containing kidney stones, primary hyperparathyroidism (an overactive parathyroid gland raising blood calcium), sarcoidosis (an inflammatory disease that also raises it) and advanced chronic kidney disease each compound the calcium load; inflammatory bowel disease worsens acid-load tolerance.
  • Age-related considerations: Kidney filtration and vascular compliance both decline with age, so the same calcium increment carries more consequence at the older end of the target range.

Key Interactions & Contraindications

  • Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide): Caution. These reduce urinary calcium excretion; combined with calcium-bound formulations they can push serum calcium high enough to cause nausea, confusion and arrhythmia. Serum calcium is rechecked at 4–8 weeks.
  • Activated vitamin D analogues (calcitriol, alfacalcidol, paricalcitol): Caution. Additive rise in calcium absorption and serum calcium. The adjustment falls on the supplement rather than the prescribed analogue, with the calcium-bound salt reduced or omitted.
  • Cardiac glycosides (heart-failure and rate-control drugs; digoxin): Caution. Any rise in serum calcium potentiates glycoside toxicity, risking arrhythmia. Calcium-free forms are preferable; where the calcium salt is used, calcium and digoxin levels are monitored.
  • Mutant-enzyme inhibitors (ivosidenib, enasidenib, olutasidenib): Absolute contraindication in the setting these drugs treat. The therapeutic aim is to starve a mutated enzyme of ketoglutaric acid; supplementing works against it directly.
  • Antibiotics, thyroid replacement and bisphosphonates (bone-density drugs; doxycycline, ciprofloxacin, levofloxacin, levothyroxine, alendronate): Monitor. Calcium binds these in the gut and cuts absorption, risking treatment failure. Dosing is separated by at least four hours.
  • Over-the-counter antacids and calcium supplements (calcium carbonate, calcium citrate, combined antacids): Caution. Straight duplication of the calcium load, with hypercalcaemia (high blood calcium) and constipation as consequences. All calcium sources count against a single daily total.
  • Over-the-counter high-dose vitamin D: Caution. Doses above 4,000 international units daily raise calcium absorption and can unmask hypercalcaemia when stacked with a calcium-bound salt. 25-hydroxyvitamin D is checked beforehand.
  • Supplement interactions — arginine and citrulline: Monitor. Both drive nitric oxide production and widen blood vessels; stacked with arginine-bound ketoglutarate they can produce additive blood-pressure lowering, flushing and light-headedness.
  • Supplement interactions — glutamine and other keto-acid salts: Caution. Glutamine, creatine α-ketoglutarate and ornithine α-ketoglutarate all feed the same pool, so combining them silently multiplies the effective dose and the acid load.
  • Additive supplements — iron and vitamin C: Potentiating, not adverse. Both are required cofactors for the enzyme family this compound feeds, so they plausibly amplify its effects; they also amplify any unwanted effects on the same enzymes.
  • Other interventions — topical or oral minoxidil: Monitor. Mechanistically the compound may oppose two enzyme actions attributed to minoxidil. Where both are used, minoxidil response is judged on standardised photography rather than impression.

  • Populations who should avoid Ketoglutaric Acid:

    • Hypercalcaemia (albumin-corrected serum calcium above 10.5 mg/dL) or untreated primary hyperparathyroidism
    • History of calcium-containing kidney stones, or hypercalciuria (excess urinary calcium) above 300 mg/24 h in men and 250 mg/24 h in women, for calcium-bound forms
    • Chronic kidney disease stage 4 or 5 (estimated filtration rate below 30 mL/min/1.73 m²)
    • Active malignancy known to carry an IDH1 or IDH2 mutation
    • Granulomatous disease with dysregulated vitamin D activation, including sarcoidosis and active tuberculosis
    • Pregnancy and lactation, where no human safety data exist for supplemental doses

Risk Mitigation Strategies

  • Calcium-free salt where calcium is the concern: Sodium α-ketoglutarate or the free acid removes the ~220 mg elemental calcium per gram, eliminating the added calcium load behind the vascular and kidney-stone concerns.
  • Total daily elemental calcium capped at 1,000 mg from all sources: The supplement, any separate calcium tablet, antacids and dairy all count towards that total. This prevents the cumulative excess linked to raised myocardial infarction rates in pooled trials.
  • 500 mg starting dose with titration over two weeks: Half the usual 1 g trial dose for 10–14 days, then full dose if tolerated. This limits nausea, reflux and diarrhoea from the acid load.
  • Dosing with a meal in a delayed-release form: Food buffers the dicarboxylic acid and delayed release moves dissolution past the stomach, directly targeting gastrointestinal intolerance.
  • Serum calcium and kidney filtration at baseline and 8–12 weeks: Catches drifting hypercalcaemia and falling filtration before symptoms appear, which matters most alongside thiazides, vitamin D analogues or digoxin.
  • Four-hour separation from calcium-binding medications: Applies to doxycycline, fluoroquinolones (a common antibiotic class), levothyroxine and bisphosphonates, and prevents the treatment failure caused by binding in the digestive tract.
  • Exclusion of an IDH-mutant malignancy before starting under oncology care: A single question to the treating team avoids supplying substrate to a mutated enzyme that converts it into a tumour-promoting metabolite.

Therapeutic Protocol

  • Baseline standard protocol: 1 g daily of sustained-release calcium α-ketoglutarate, the dose and form used in the largest human trial. Sports-nutrition practice instead runs 3.6–6 g of the plain salt.
  • Competing approach — topical or compounded application: The only hair-positive experiment applied the compound to skin, not by mouth. Neither route has human hair data, so neither can be treated as the default.
  • Who popularised each approach: Oral aging-research dosing traces to the Buck Institute mouse lifespan study of Brian Kennedy and Gordon Lithgow, and to Ponce de Leon Health; the topical hair route to Jing Huang’s UCLA group.
  • Best time of day: With the largest meal, most often breakfast. No circadian data exist for this compound; the timing choice is driven by gastric tolerance and by calcium absorption, which is better in divided daytime doses.
  • Half-life: No dedicated human half-life study exists. As a cycle intermediate it is consumed within minutes, which is why sustained- and delayed-release formulations were developed for the human trials.
  • Single versus split dosing: At 1 g a single dose is standard. Above 2 g, splitting into two or three doses improves gastric tolerance and keeps any single calcium bolus under 500 mg, the threshold above which absorption efficiency falls.
  • Genetic polymorphisms influencing dose: CASR variants that loosen calcium regulation argue for a calcium-free salt; known IDH1 or IDH2 tumour mutations rule the compound out rather than adjust the dose.
  • Sex-based differences: Mouse benefits on coat colour and survival were female-predominant. In humans, post-menopausal women carry the greatest background calcium exposure, so the carrier choice matters more than the ketoglutarate dose.
  • Age-related considerations: Endogenous levels fall with age, so older users have the most headroom; against that, reduced kidney filtration past 65 argues for the lower end of the range and a calcium-free salt.
  • Baseline biomarkers influencing response: Protocols put ferritin, 25-hydroxyvitamin D and thyroid function in range first, since deficiency in any of them independently sustains shedding and will mask or mimic a response.
  • Pre-existing conditions influencing response: Scarring alopecia will not respond at any dose. Active inflammatory bowel disease limits tolerance of the acid load, and advanced kidney disease limits clearance.

Discontinuation & Cycling

  • Intended duration: Framed as open-ended in aging-research use, since the rationale is replacing an age-related decline. For hair specifically, no duration has been validated, so any horizon is arbitrary.
  • Withdrawal effects: None documented. As an endogenous metabolite with minutes-long turnover, blood levels simply return to baseline; no rebound has been reported in any human or animal study.
  • Tapering protocol: Not applicable. There is no receptor adaptation or dependence to unwind, so it can be stopped outright. Any calcium supplement taken alongside follows its own tapering considerations.
  • Cycling for efficacy: No evidence supports cycling. Tolerance has not been described, and the mouse studies used continuous dietary exposure for six months or longer without a documented fade in effect.
  • Practical stop rule for hair use: With no human hair data, a fixed review point — twelve months, matched to two full follicle cycles — is the only defensible way to avoid indefinite use without a signal.

Sourcing and Quality

  • Salt form determines the calcium load: Calcium α-ketoglutarate carries about 22% elemental calcium; sodium α-ketoglutarate and the free acid carry none. The difference is large enough that the form is not interchangeable with whatever the longevity brands stock.
  • Release profile: Plain powder dissolves in the stomach and is largely consumed before reaching tissues. Delayed- and sustained-release capsules were developed for the human trials and are what those trials actually tested.
  • Combination salts carry a second active ingredient: Arginine and ornithine salts add an amino acid with its own effects; creatine α-ketoglutarate adds creatine. The salt name, not the marketing term, identifies the actual content.
  • Third-party testing: A certificate of analysis and a testing mark such as United States Pharmacopeia Verified, NSF Certified for Sport, or Informed Choice confirm identity, stated dose and absence of heavy metals.
  • Brands identified by independent testers: ConsumerLab names ProHealth Longevity and Renue by Science for the calcium salt, and Rejuvant for the vitamin-combined delayed-release product; it also notes the calcium salt costs several times the plain form.
  • Handling and stability: The free acid draws in moisture and is sour; capsules stored in humidity clump and degrade. Sealed capsules hold up better than bulk powder, and caked product has already degraded.

Practical Considerations

  • Time to effect: Unknown for hair in humans. Mouse follicles entered growth within weeks, but the human cycle means any real change needs 6–12 months and standardised photography to detect.
  • Common pitfall — expecting a minoxidil-like response: The evidence base here is animal and cell work only. Treating it as an established regrowth agent, or substituting it for one with human trial data, is the central error.
  • Common pitfall — double-counting calcium: Users stack the calcium salt on top of a calcium tablet and a calcium-fortified diet without ever totalling the elemental calcium, which is where the main documented risk lives.
  • Common pitfall — no baseline photography: Without standardised, fixed-distance baseline images, a 6–12 month assessment is guesswork, and seasonal shedding will be misread as either benefit or harm.
  • Regulatory status: Sold in the United States as a dietary supplement under the Dietary Supplement Health and Education Act, so no pre-market efficacy or safety review by the Food and Drug Administration applies. No hair indication is approved anywhere.
  • Cost and accessibility: Widely available without prescription. The plain salt is inexpensive; calcium-bound and delayed-release longevity products run several times higher, which matters over the 12-month horizon any hair assessment requires.

Interaction with Foundational Habits

  • Sleep: Indirect and unquantified. It feeds the glutamate pool from which GABA (the brain’s main calming signal) is made, but no human study has measured sleep on it. Practically, gastric discomfort at gram doses argues for morning rather than bedtime dosing.
  • Nutrition: Direct and cofactor-dependent. The enzyme family it feeds requires iron and vitamin C, so adequate status of both plausibly determines whether extra substrate does anything. Dosing falls with the largest meal; the calcium salt counts against total daily calcium, and protein intake supplies the same pool through glutamine.
  • Exercise: Potentiating in principle. Exercise raises endogenous levels, and the compound has been studied for muscle regeneration and atrophy resistance, so the two act on overlapping targets. No timing advantage around workouts has been demonstrated; the sports-nutrition dosing tradition of pre-workout use rests on the arginine salt, not the ketoglutarate.
  • Stress management: Indirect. Psychological stress drives telogen effluvium (the diffuse shedding that pushes follicles out of growth), which is exactly the transition this compound is proposed to reverse. No human study has measured cortisol or stress response on it, so any interaction is inferred from the shared endpoint rather than demonstrated.

Monitoring Protocol & Defining Success

Before starting, the sensible baseline covers two things: the safety markers affected by the calcium carrier, and the hair markers that would otherwise confound any judgement of effect. The baseline panel is drawn fasting and includes albumin-corrected serum calcium, parathyroid hormone, 25-hydroxyvitamin D, estimated kidney filtration rate, ferritin and thyroid-stimulating hormone. It is paired with standardised scalp photographs at fixed distance, lighting and part line, plus a hair density count where a trichoscope (magnified scalp imaging device) is available. The safety panel is repeated at 8–12 weeks, then every 6–12 months on stable dosing; photography is repeated at 6 and 12 months, since two full follicle cycles pass before any change is interpretable. Starting a thiazide diuretic, a vitamin D analogue or digoxin brings the panel forward.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum calcium (albumin-corrected) 9.0–9.8 mg/dL Detects the calcium load from calcium-bound forms Conventional range extends to 10.2–10.5 mg/dL; the tighter functional target flags drift earlier. Fasting draw
Parathyroid hormone, intact 15–35 pg/mL Confirms calcium regulation is intact before adding a calcium salt PTH is parathyroid hormone, the calcium set-point regulator. Conventional range 10–65 pg/mL. Best paired with calcium and vitamin D on the same draw
25-hydroxyvitamin D 40–60 ng/mL Governs how much of the added calcium is absorbed Conventional threshold is merely “above 30 ng/mL”. Values above 80 ng/mL plus a calcium salt raise hypercalcaemia risk
Estimated glomerular filtration rate Above 90 mL/min/1.73 m² Surplus is cleared renally; falling filtration concentrates the load eGFR is estimated glomerular filtration rate, the kidney’s filtering capacity. Conventional concern starts below 60. Creatine supplements in the 48 h before the draw distort the result
Ferritin 50–150 ng/mL Low iron independently sustains hair shedding and starves the target enzymes of their cofactor Conventional range starts as low as 15 ng/mL, far below the level at which hair recovers. Rises with inflammation, so interpret alongside C-reactive protein (a general marker of inflammation)
Thyroid-stimulating hormone 0.5–2.5 mIU/L Thyroid dysfunction is the commonest reversible cause of diffuse shedding Conventional upper limit is 4.0–4.5 mIU/L. Morning draw; values vary through the day
High-sensitivity C-reactive protein Below 1.0 mg/L Tracks the inflammatory tone the compound is claimed to lower, and contextualises ferritin Conventional reporting treats up to 3.0 mg/L as average risk and only flags above that; the tighter functional target is stricter. A result within two weeks of any infection is uninterpretable, since infection raises it independently of the supplement
Hair density (magnified scalp imaging, hairs/cm²) No established target; track change from the individual’s own baseline The only direct readout of the claimed effect Same site, same device, same part line each time. Absolute values differ between devices, so only within-person change is meaningful

Qualitative markers worth tracking alongside the labs:

  • Shedding volume on a fixed weekly count, such as hairs collected after a standardised wash
  • Regrowth of short, pigmented hairs along the hairline and part, distinct from fine, colourless hair
  • Perceived hair calibre and the feel of ponytail thickness
  • Scalp comfort — itching, tenderness or flaking, which point to a different diagnosis
  • Gastrointestinal comfort at the chosen dose and form
  • Energy and exercise recovery, the domains where the compound has its firmest human data

Emerging Research

  • Largest human trial of the compound: NCT05706389, the ABLE trial, randomises 120 adults aged 40–60 with an elevated methylation age to 1 g sustained-release calcium α-ketoglutarate or placebo for six months. Primary endpoint is methylation age; no hair measure is included.
  • Manufacturer-run safety and biomarker study: NCT04821401 enrolled 100 participants on the vitamin-combined product with C-reactive protein as primary endpoint. Sponsored by Ponce de Leon Health, which sells it — a direct financial interest in the result.
  • Independent replication attempt in aging: NCT07114536 tests calcium α-ketoglutarate in 30 participants over 12 weeks against a composite biological-age score, sponsored by a Chinese biotechnology firm. Small, and again vendor-linked.
  • Evidence that could weaken the case: NCT07031128, a 250-patient Phase 4 surgical trial, and NCT04723888, a 300-patient aneurysm trial, are the first adequately powered safety exposures. Null or adverse findings there would constrain enthusiasm well before hair is studied.
  • Combination confounding: NCT07475546 bundles multiple agents in 30 participants, so any positive result will not isolate this compound. Combination designs currently outnumber single-agent ones in this field.
  • The unaddressed question: No registered trial anywhere measures a hair, scalp or follicle outcome for this compound. Until one exists, the hair case rests on Chai et al., 2019 and the rabbit work of Wang et al., 2025.
  • Where the mechanism could be settled: A study co-administering it with minoxidil would test the lysyl hydroxylase opposition directly. That experiment, which could strengthen or sink the rationale, has not been registered.

Conclusion

Ketoglutaric acid is a substance the body makes every minute of the day while turning food into energy, sold as a supplement in several salt forms. The case for it as a hair-regrowth agent rests entirely on laboratory and animal work: mouse skin pushed from rest into active growth, rabbits with denser coats, follicle-instructing cells shielded from chemical stress, and older female mice keeping their fur colour. No study in people has measured hair count, thickness or density on this compound. The only human-derived hair finding, drawn from inherited differences in natural blood levels rather than from taking a supplement, points toward more patchy autoimmune hair loss rather than less.

The mechanisms cut both ways. The same enzyme family the compound feeds includes one whose activity a standard hair drug is thought to suppress, so more of it could in principle work against that drug rather than with it. Nobody has tested this.

Safety looks unremarkable at the doses used in aging research, with the practical caveats attached to the calcium carrier and to stomach tolerance rather than to the molecule itself.

Much of the supportive human aging data comes from parties who sell the product or hold patents on its use, and no independent group has reproduced it. For a proactive, risk-aware audience willing to act on thin evidence, that combination places it at the far speculative end of the hair-regrowth field: biologically interesting, commercially promoted, clinically untested.

Top - Benefits - Risks - Protocol